文献速递认知障碍与痴呆

无认知障碍成人中载脂蛋白E ε2与ε4、年龄及β-淀粉样蛋白的关联

Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment.
PubMed 文献 · JAMA Neurol · 2021-01-01

这项横断面研究利用A4研究筛选数据,纳入4432名65至85岁无认知障碍成人,分析APOE基因型与18F-florbetapir PET测得的Aβ沉积及认知的关系。结果显示,在携带ε4等位基因的情况下,ε2等位基因与总体及年龄依赖性Aβ水平降低相关,且ε4携带者认知表现下降完全由Aβ介导。

要点

  • 在ε4存在时,ε2等位基因与Aβ沉积减少相关,且年龄增长所致Aβ增加速率不足ε34组的一半。
  • ε4携带者认知表现低于非携带者,该差异完全由Aβ沉积介导。
  • Aβ与认知评分下降的关联不因APOE基因型而异。

核心结论

  • 在携带ε4等位基因的情况下,ε2等位基因对Aβ沉积具有保护作用,提示模拟ε2功能促进ε4携带者Aβ清除的治疗策略具有潜力。

研究设计与样本

  • 横断面研究,使用A4研究2014年4月至2017年12月的筛选数据,纳入4432名65至85岁无认知障碍成人。

主要发现

  • APOE ε2与总体Aβ水平降低相关:ε24组SUVR为1.11(95%CI 1.08-1.14),ε34组为1.18(95%CI 1.17-1.19)。

临床怎么用

  • 对于ε4携带者,针对Aβ通路的早期干预可能延缓Aβ累积,但需进一步临床试验验证。

局限性

  • 横断面设计无法确定因果关系,结果基于无认知障碍的筛选人群,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although the most common recent approach in Alzheimer disease drug discovery is to directly target the β-amyloid (Aβ) pathway, the high prevalence of apolipoprotein E ε4 (APOE ε4) in Alzheimer disease and the ease of identifying ε4 carriers make the APOE genotype and its corresponding protein (apoE) an appealing therapeutic target to slow Aβ accumulation. OBJECTIVE: To determine whether the ε2 allele is protective against Aβ accumulation in the presence of the ε4 allele and evaluate how age and the APOE genotype are associated with emerging Aβ accumulation and cognitive dysfunction. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used screening data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease Study (A4 Study) collected from April 2014 to December 2017 and analyzed from November 2019 to July 2020. Of the 6943 participants who were a part of the multicenter clinical trial screening visit, 4432 were adults without cognitive impairment aged 65 to 85 years who completed a fluorine 18-labeled (18F)-florbetapir positron emission tomography scan, had APOE genotype information, and had a Clinical Dementia Rating of 0. Participants who were taking a prescription Alzheimer medication or had a current serious or unstable illness that could interfere with the study were excluded. MAIN OUTCOMES AND MEASURES: Aβ pathology, measured by 18F-florbetapir positron emission tomography and cognition, measured by the Preclinical Alzheimer Cognitive Composite. RESULTS: A total of 4432 participants were included (mean [SD] age, 71.3 [4.7] years; 2634 women [59.4%]), with a mean (SD) of 16.6 (2.8) years of education and 1512 (34.1%) with a positive Aβ level. APOE ε2 was associated with a reduction in both the overall (standardized uptake value ratio [SUVR], ε24, 1.11 [95% CI, 1.08-1.14]; ε34, 1.18 [95% CI, 1.17-1.19]) and the age-dependent level of Aβ in the presence of ε4, with Aβ levels in the APOE ε24 group (n = 115; ε24, 0.005 SUVR increase per year of age) increasing at less than half the rate with respect to increasing age compared with the APOE ε34 group (n = 1295; 0.012 SUVR increase per year of age; P = .04). The association between Aβ and decreasing Preclinical Alzheimer Cognitive Composite scores did not differ by APOE genotype, and the reduced performance on the Preclinical Alzheimer Cognitive Composite in APOE ε4 carriers compared with noncarriers was completely mediated by Aβ (unadjusted difference in composite scores between ε4 carriers and noncarriers = -0.084, P = .005; after adjusting for 18F-florbetapir = -0.006, P = .85; after adjusting for 18F-florbetapir and cardiovascular scores = -0.009, P = .78). CONCLUSIONS AND RELEVANCE: These findings suggest that the protective outcome of carrying an ε2 allele in the presence of an ε4 allele against Aβ accumulation is important for potential treatments that attempt to biochemically mimic the function of the ε2 allele in order to facilitate Aβ clearance in ε4 carriers. Such a treatment strategy is appealing, as ε4 carriers make up approximately two-thirds of patients with Alzheimer disease dementia. This strategy could represent an early treatment option, as many ε4 carriers begin to accumulate Aβ in early middle age.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Insel PS, Hansson O, Mattsson-Carlgren N, et al. Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment. JAMA Neurol. 2021. PMID: 33044487. doi:10.1001/jamaneurol.2020.3780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。